ReproCELL Incorporated (4978.T)
- Previous Close
136.00 - Open
136.00 - Bid 135.00 x --
- Ask 136.00 x --
- Day's Range
134.00 - 137.00 - 52 Week Range
132.00 - 329.00 - Volume
115,900 - Avg. Volume
550,008 - Market Cap (intraday)
11.484B - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
-- - EPS (TTM)
-2.58 - Earnings Date May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, pluripotent stem cells, and synfire induced neurons; 3D cell culture; and labware. The company also provides research stem cell, genomics, clinical stem cell research, preclinical and drug discovery CRO, precision medicine, human tissue samples, clinical laboratory, diagnostic, and gene editing services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.
www.reprocell.comRecent News: 4978.T
Performance Overview: 4978.T
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4978.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4978.T
Valuation Measures
Market Cap
11.57B
Enterprise Value
5.70B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.62
Price/Book (mrq)
1.50
Enterprise Value/Revenue
2.27
Enterprise Value/EBITDA
-26.24
Financial Highlights
Profitability and Income Statement
Profit Margin
-8.70%
Return on Assets (ttm)
-3.29%
Return on Equity (ttm)
-2.82%
Revenue (ttm)
2.51B
Net Income Avi to Common (ttm)
-218M
Diluted EPS (ttm)
-2.58
Balance Sheet and Cash Flow
Total Cash (mrq)
6.35B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Research Analysis: 4978.T
Company Insights: 4978.T
4978.T does not have Company Insights